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Dual role of YM1+ M2 macrophages 
in allergic lung inflammation
Christina Draijer1,2, Patricia Robbe2,3, Carian E. Boorsma1,2, Machteld N. Hylkema  2,3 & 
Barbro N. Melgert  1,2
Alternatively activated (M2 or YM1+) macrophages have been associated with the development 
of asthma but their contribution to disease initiation and progression remains unclear. To assess 
the therapeutic potential of modulating these M2 macrophages, we have studied inhibition of M2 
polarisation during and after development of allergic lung inflammation by treating with cynaropicrin, 
a galectin-3 pathway inhibitor. Mice that were treated with this inhibitor of M2 polarisation during 
induction of allergic inflammation developed less severe eosinophilic lung inflammation and less 
collagen deposition around airways, while the airway α-smooth muscle actin layer was unaffected. 
When we treated with cynaropicrin after induction of inflammation, eosinophilic lung inflammation and 
collagen deposition were also inhibited though to a lesser extent. Unexpectedly, both during and after 
induction of allergic inflammation, inhibition of M2 polarisation resulted in a shift towards neutrophilic 
inflammation. Moreover, airway hyperresponsiveness was worse in mice treated with cynaropicrin as 
compared to allergic mice without inhibitor. These results show that M2 macrophages are associated 
with remodeling and development of eosinophilic lung inflammation, but prevent development of 
neutrophilic lung inflammation and worsening of airway hyperresponsiveness. This study suggests that 
macrophages contribute to determining development of eosinophilic or neutrophilic lung inflammation 
in asthma.
Allergic asthma is a heterogeneous disorder of the lungs and those affected suffer from symptoms such as wheez-
ing, coughing and chest tightness. These symptoms are caused by lung inflammation, airway hyperresponsiveness 
(AHR), mucus hypersecretion, and airway wall remodeling, often due to exposure to allergens such as house 
dust mite (HDM). The lung inflammation is characterized by increased infiltration of Th2 lymphocytes, produc-
tion of Th2 cytokines interleukin(IL)-4, IL-13, and IL-5, and increased numbers of mast cells, eosinophils and 
macrophages1.
What kind of role macrophages play in asthma has been the subject of much debate recently. On the one 
hand studies have shown macrophages to be important in maintaining lung homeostasis and protecting 
against inflammation2–6, but others studies, including our own, have shown that macrophages can contribute 
to development and severity of asthma5,7–14. These different findings may be due to the plastic behavior of mac-
rophages. Macrophages can adopt many different polarisation states depending on the signals they receive from 
tissues. These polarisation states range from a proinflammatory state with expression of interferon regulatory 
factor 5 (IRF5, also known as classically activated or M1 macrophages) to a prorepair state with expression of 
chitinase-like protein-3 (YM1/Chi3l3) (also known as alternatively activated or M2 macrophages) and an 
anti-inflammatory state with expression of IL-10 (also known as M2-like macrophages)8,15–17.
Allergic asthma is characterized by the presence of high levels of IL-4 and IL-13 that can induce M2 polari-
sation and therefore, not surprisingly, we and others have found higher numbers of these macrophages in lungs 
of asthma patients and mice with allergic lung inflammation as compared to controls7,8,11,14. We also showed that 
the presence of higher numbers of these macrophages correlated with having worse symptoms8. In addition, 
transfer of IL-4/IL-13-stimulated macrophages to allergic mice aggravated the allergic inflammatory response 
in the lungs, suggesting that these macrophages contribute to the disease7,9,10. However, we have also shown that 
both human asthma as well as experimental asthma in mice is characterized by high numbers of IRF5+ M1 mac-
rophages and low numbers of IL-10+ M2-like macrophages as compared to control14. In addition, having high 
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numbers of IRF5+ M1 macrophages correlated with lower lung function, while having more IL-10+ M2-like 
macrophages correlated with better lung function14. Therefore a picture emerges of asthma being a disease in 
which homeostatic control of inflammation by IL-10+ M2-like macrophages is lost due to polarisation towards 
M1 and/or M2. This view is reinforced by studies showing less severe lung inflammation when adoptively trans-
ferring M2-like macrophages into the lungs of mice with allergic airway inflammation or studies steering M2 
polarisation towards M2-like polarisation with the anti-inflammatory, innate immune plasma protein, serum 
amyloid P9,13.
Directing macrophage polarisation towards an anti-inflammatory M2-like behavior therefore appears to be 
a therapeutic option in asthma. A remaining question is whether inhibition of M2 polarisation per se will have 
a similar effect and will shift macrophage polarisation towards more anti-inflammatory behavior. To investigate 
this we inhibited M2 polarisation during and after development of HDM-induced lung inflammation by treating 
with cynaropicrin, a galectin-3 pathway inhibitor that potently inhibits M2 polarisation18.
Results
Treatment with cynaropicrin inhibits M2 macrophage polarisation. To confirm previous findings, 
we tested the potential of cynaropicrin to inhibit polarisation into M2 macrophages. After two weeks or two 
weeks plus one day of HDM-exposures, the M2-related cytokine YM1 was found to be significantly higher in 
bronchoalveolar lavage fluid (BALF) as compared to PBS controls (Fig. 1A and B). Treatment of HDM-exposed 
mice with cynaropicrin resulted in lower YM1 levels in BALF compared to nontreated HDM-exposed mice, 
although this difference was only significant when treatment was started during induction of airway inflamma-
tion and not after induction.
To identify M2 macrophages in lung tissue, YM1 was stained in combination with a general macrophage 
marker (Mac3). More YM1+ macrophages were found in lungs of HDM-exposed mice than in lungs of healthy 
controls. Cynaropicrin-treatment resulted in significantly fewer YM1+ macrophages in lungs of mice treated 
during induction of allergic lung inflammation. Treatment of mice with established allergic lung inflamma-
tion showed a similar pattern in lowering YM1+ macrophage numbers, but the differences were not significant 
(Fig. 1C and D).
Treatment with cynaropicrin dampens HDM-induced allergic lung inflammation. To assess the 
therapeutic potential of modulating YM1+ macrophages, we tested whether inhibition of M2 polarisation by 
cynaropicrin would affect induction of allergic lung inflammation and whether it would diminish an exacerba-
tion in already established allergic lung inflammation. The presence of eosinophils, (MHCII-expressing) mac-
rophages, T cell subsets and Th2-related cytokines was examined in lung tissue and BALF to assess allergic lung 
inflammation.
HDM exposure induced higher numbers of eosinophils, total and MHCII-expressing macrophages (Fig. 2A,C 
and E), CD4+ T cells, effector T cells, regulatory T cells (Table 1) in lungs as compared to healthy controls. 
Inhibition of M2 polarisation during induction of allergic lung inflammation resulted in lower numbers of eosin-
ophils and less expression of MHCII on macrophages. Total numbers of macrophages, CD4+ T cells, effector T 
cells and regulatory T cells were not affected by cynaropicrin treatment.
In mice with established allergic lung inflammation, that were treated with cynaropicrin afterwards, similarly 
low numbers of eosinophils were found in lungs as compared to vehicle-treated HDM-exposed mice (Fig. 2B). 
Total numbers of macrophages (Fig. 2D), CD4+ T cells, effector T cells and regulatory T cells (Table 1) were not 
affected by cynaropicrin treatment in established allergic lung inflammation, but macrophages were found to 
express less MHCII after treatment (Fig. 2F).
Higher levels of the M2 macrophage-associated cytokines IL-4 and IL-13 were found after two weeks of 
HDM-exposure as compared to healthy controls (Table 2). Cynaropicrin-treatment resulted in lower levels of 
IL-13 in lungs of mice that were treated during induction of allergic lung inflammation.
In mice with established allergic lung inflammation IL-4 and IL-13 levels were similar to those in lungs of 
healthy controls. Cynaropicrin treatment of mice with established allergic lung inflammation did not affect levels 
of IL-4 and IL-13 (Table 2).
Treatment with cynaropicrin changes the balance in predominant macrophage phenotypes. 
Since cynaropicrin treatment inhibits M2 polarisation of macrophages, but total macrophage numbers were not 
affected, the presence of macrophage phenotypes was studied. To identify different macrophage phenotypes, lung 
tissue was dual stained for the Mac3 macrophage marker and either YM1, IRF5, or IL-10.
As shown in Fig. 1, mice exposed to HDM had more YM1+ macrophages in lungs compared to healthy 
controls and cynaropicrin-treatment resulted in significantly lower numbers of YM1+ macrophages in lungs of 
mice treated during induction of allergic lung inflammation (Fig. 1C and D). Treatment of mice with established 
allergic lung inflammation showed a similar pattern in lowering YM1+ macrophage numbers, but the differences 
were not significant. Higher numbers of IRF5+ macrophages were observed after HDM-exposure as compared 
to healthy controls, but even more IRF5+ macrophages were found in mice treated with cynaropicrin during 
and after induction of allergic lung inflammation (Fig. 3A and B). Numbers of IL-10+ macrophages were lower 
in allergic lungs than in healthy lungs. Treatment of allergic mice with cynaropicrin during or after induction of 
inflammation did not affect the low numbers of IL-10+ macrophages (Fig. 3C and D). These results were sup-
ported by a trend towards lower levels of IL-10 that we found in lung tissue of HDM-treated mice in both models 
and the inability of cynaropicrin treatment to increase these levels again (Table 2).
Treatment with cynaropicrin results in neutrophilic lung inflammation. Cynaropicrin-treatment 
resulted in more IRF5+ macrophages, suggesting that a different type of inflammation is induced. We further 
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studied the lung inflammation and found more neutrophils in lungs of allergic mice as compared to healthy con-
trols and even more neutrophils were found in lungs of mice that were treated with cynaropicrin both during and 
after induction of allergic lung inflammation (Fig. 4A and B).
Furthermore, we observed higher levels of IRF5+ macrophage-related cytokines IL-12, IFNγ and TNFα in 
allergic lungs in comparison to healthy controls (Table 3). Cynaropicrin-treatment during induction of aller-
gic lung inflammation resulted in even higher levels of IL-12, IFNγ and TNFα as compared to HDM-exposed 
Figure 1. Treatment with cynaropicrin inhibits M2 macrophage polarisation. YM1 levels in BALF (A and B) 
of healthy mice (n = 8), vehicle-treated HDM-exposed mice (n = 16) and HDM-exposed mice treated with 
cynaropicrin (n = 8) during (left) and after (right) induction of allergic lung inflammation. The number of 
YM1 + Mac3 + macrophages (C and D) in lungs of healthy mice (n = 8), vehicle-treated HDM-exposed mice 
(n = 16) and HDM-exposed mice treated with cynaropicrin (n = 8) during (left) and after (right) induction 
of allergic lung inflammation. Representative pictures of the YM1 + Mac3 + double staining are shown in the 
bottom. Nuclear counter staining was not used to maximize visibility of double-positive cells (magnification 
200x). Inserts are close up magnifications (magnification 400x) of double-positive cells. Significance was tested 
using a one-way ANOVA followed by Sidak’s multiple comparisons test comparing healthy vs. HDM + vehicle 
and HDM + vehicle vs. HDM + cynaropicrin.
www.nature.com/scientificreports/
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vehicle-treated mice. A similar pattern was seen when mice with established lung inflammation were treated with 
cynaropicrin, although these differences were not significant.
In view of the higher number of neutrophils found after cynaropicrin treatment, we also assessed levels of 
IL-17 in lung tissue (Table 3). Indeed, HDM-treatment resulted in higher levels of IL-17 as compared to healthy 
mice, but cynaropicrin treatment did not affect these levels any further. In addition, we did not see any correla-
tions between IL-17 levels and neutrophil counts (data not shown).
Treatment with cynaropicrin worsened airway hyperresponsiveness. Inhibition of M2 polarisa-
tion by cynaropicrin dampened eosinophilic lung inflammation, but induced neutrophilic lung inflammation. 
However, both eosinophilic and neutrophilic lung inflammation can be accompanied by airway hyperrespon-
siveness. Therefore, we tested whether airway hyperresponsiveness would be affected by cynaropicrin-treatment.
HDM exposure induced a dose-dependent increase in airway hyperresponsiveness to methacholine, which 
was significantly higher as compared to PBS-exposed controls (Fig. 5A and B). Cynaropicrin-treatment, both 
Figure 2. Cynaropicrin treatment dampens HDM-induced eosinophilic inflammation and macrophage 
activation. Number of eosinophils (A and B), numbers of alveolar macrophages (C and D) and expression 
of MHC class II on alveolar macrophages (E and F) in lungs of healthy mice (n = 8), vehicle-treated HDM-
exposed mice (n = 16) and HDM-exposed mice treated with cynaropicrin (n = 8) during (left) and after (right) 
induction of allergic lung inflammation. Significance was tested using a one-way ANOVA followed by Sidak’s 
multiple comparisons test comparing healthy vs. HDM+ vehicle and HDM+ vehicle vs. HDM+ cynaropicrin.
www.nature.com/scientificreports/
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during and after induction of allergic lung inflammation, increased airway hyperresponsiveness to methacholine 
even further.
Treatment with cynaropicrin results in less airway fibrosis. In order to shed some more light on the 
mechanism behind the worsening of airway hyperresponsiveness after inhibition of M2 polarisation, we studied 
the effect of cynaropicrin-treatment on airway remodeling and fibrosis.
Airways of HDM-exposed mice showed more remodeling than airways of control mice as reflected by a 
thicker layer of α-smooth muscle actin (α-SMA) and more collagen I and III deposition around the airways 
(Fig. 6A–D). Cynaropicrin-treatment both during and after induction of allergic lung inflammation did not affect 
the thickness of the α-SMA layer, but did result in significantly lower collagen deposition.
Discussion
This study reveals an important dual role of YM1+ M2 macrophages in allergic lung inflammation. M2 mac-
rophages are present in high numbers in lungs of humans and mice with allergic lung inflammation7,8,11,12,19, but 
their role in this disease remains controversial. By investigating the inhibition of M2 polarisation in mice during 
and after development of allergic lung inflammation, we found that YM1+ M2 macrophages are associated with 
both induction and progression of eosinophilic lung inflammation, but on the other hand prevent development 
of neutrophilic inflammation. In addition, YM1+ M2 macrophages contribute to airway remodeling, but thereby 
protect against the development of more severe airway hyperresponsiveness.
The treatment with cynaropicrin, an inhibitor of M2 polarisation, during and after induction of allergic lung 
inflammation dampened eosinophilic lung inflammation. These findings further substantiate previous findings 
that showed participation of M2 macrophages in T helper 2-mediated inflammatory diseases. We showed that 
the transfer of in vitro differentiated M2 macrophages into the airways of male asthmatic mice aggravated lung 
inflammation7. A study by Ford et al. showed that intraperitoneal injection of IL-4Rα-positive macrophages was 
sufficient to increase the allergic inflammatory response in the lung10. In a model of fungus-induced allergic 
airway disease, Moreira et al. showed that transfer of IL-4/IL-13-stimulated macrophages into the lungs of mice 
enhanced both inflammation and collagen deposition as compared to asthmatic mice not treated with these mac-
rophages9. In contrast, Nieuwenhuizen et al. demonstrated that M2 macrophages are not necessary for allergic 
airway disease and may only be an association as a result of the elevated Th2 response20. They showed that airway 
hyperresponsiveness, remodeling and eosinophilic inflammation were not affected by decreased development 
of M2 macrophages by using LysMcre mice with macrophage-restricted IL-4 receptor-α (IL-4Rα)-deficiency. 
Interestingly, recent data showed that these LysMcre mice successfully abrogate IL-4Rα signaling on mature tis-
sue resident macrophages, but fail to delete this on more immature macrophages arising from proliferation or 
from recruited monocyte precursors21. In addition, it was found that M2 macrophages derived from monocytes 
or from tissue macrophages are phenotypically and functionally distinct22. Combining these findings, it seems 
likely that in particular M2 macrophages that are newly derived through either proliferation or from recruited 
monocytes, are the active contributors to the disease rather than the mature resident M2 macrophages. The use of 
the pharmacological agent cynaropicrin is an advantage in this study as this can inhibit M2 polarisation of both 
Healthy
Inhibition of alternative activation during 
induction of allergic lung inflammation
Inhibition of alternative activation after induction 
of allergic lung inflammation
HDM+ vehicle HDM+ Cynaropicrin HDM+ vehicle HDM+ Cynaropicrin
CD4+ T cells (105 cells/lung) 2.57 ± 0.28 8.89 ± 1.44 (p = 0.022) 5.88 ± 0.51 4.30 ± 0.35 (p = 0.0072) 4.28 ± 0.36
Regulatory T cells (105 cells/lung) 0.11 ± 0.02 0.81 ± 0.16 (p = 0.022) 0.47 ± 0.04 0.43 ± 0.04 (p < 0.0001) 0.45 ± 0.09
Effector T cells (105 cells/lung) 0.38 ± 0.08 1.47 ± 0.29 (p < 0.0001) 1.06 ± 0.17 0.93 ± 0.08 (p = 0.0001) 0.96 ± 0.08
Table 1. T cells in lungs and BALF of healthy mice, vehicle-treated HDM-exposed mice and HDM-exposed 
mice treated with cynaropicrin during and after induction of allergic lung inflammation. Data are presented as 
mean ± standard error of the mean (SEM). Shown p values represent the comparison of healthy versus HDM+ 
vehicle-treated mice.
Healthy
Inhibition of alternative activation during induction 
of allergic lung inflammation
Inhibition of alternative activation after 
induction of allergic lung inflammation
HDM+ vehicle HDM+ Cynaropicrin HDM+ vehicle HDM+ Cynaropicrin
Th2-related cytokines
IL-13 (pg/g lung tissue) 3.8 ± 2.2 7.3 ± 1.1 (*p = 0.044) 5.0 ± 0.3 (#p = 0.044) 2.9 ± 0.6 4.2 ± 0.7
IL-4 (pg/g lung tissue) 1.5 ± 0.6 3.3 ± 0.4 (*p = 0.0238) 2.8 ± 0.4 1.7 ± 0.3 2.3 ± 0.4
Anti-inflammatory cytokines
IL-10 (pg/g lung tissue) 12.6 ± 1.4 9.1 ± 1.1 (*p = 0.09) 10.8 ± 1.7 9.5 ± 0.6 (*p = 0.07) 7.5 ± 0.8
Table 2. Th2-related and anti-inflammatory cytokines in lungs of healthy mice, vehicle-treated HDM-
exposed mice and HDM-exposed mice treated with cynaropicrin during and after induction of allergic 
lung inflammation. Data are presented as mean ± SEM. *Represents the comparison of healthy versus 
HDM+ vehicle-treated mice, while #represents the comparison of HDM+ vehicle versus HDM+ cynaropicrin-
treated mice.
www.nature.com/scientificreports/
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newly derived and resident macrophages, as opposed to the use of knockout or overexpression models, which 
target one macrophage population only.
Our method of inhibiting alternative activation involved intranasal administration of cynaropicrin, a 
galectin-3 pathway inhibitor. Activation of the galectin-3/CD98/PI3K-pathway has previously been shown to be 
required for polarisation into YM1+ M2 macrophages. Cynaropicrin specifically inhibits the development of M2 
macrophages and does not affect other macrophage phenotypes as shown by Mackinnon et al.18. We confirmed 
their findings with preliminary in vitro and in vivo studies and in addition ruled out possible effects of toxicity 
(data not shown). It is, however, unknown how in vivo administration of cynaropicrin influences other cells in 
the lung that express galectin-3. In basal conditions a variety of cells express galectin-3, including macrophages, 
eosinophils, dendritic cells (DCs), and epithelial cells23,24. The current study did not investigate the direct impact 
Figure 3. Cynaropicrin treatment changes the balance in macrophage phenotypes. The number of IRF5 + Mac3  
+ macrophages (A and B) and IL-10 + Mac3 + macrophages (C and D) in lungs of healthy mice (n = 8), vehicle-
treated HDM-exposed mice (n = 16) and HDM-exposed mice treated with cynaropicrin (n = 8) during (left) and 
after (right) induction of allergic lung inflammation. Representative pictures of the IRF5 + Mac3 + and IL-10 +  
Mac3 + double-stainings are shown on the right. Nuclear counter staining was not used to maximize visibility of 
double-positive cells (magnification 200x). Inserts are close up magnifications (magnification 400x) of double-
positive cells. Significance was tested using a one-way ANOVA followed by Sidak’s multiple comparisons test 
comparing healthy vs. HDM+ vehicle and HDM+ vehicle vs. HDM+ cynaropicrin.
Figure 4. Cynaropicrin treatment results in neutrophilic inflammation. Number of neutrophils in lungs 
of healthy mice (n = 8), vehicle-treated HDM-exposed mice (n = 16) and HDM-exposed mice treated with 
cynaropicrin (n = 8) during (A) and after (B) induction of allergic lung inflammation. Significance was tested 
using a one-way ANOVA followed by Sidak’s multiple comparisons test comparing healthy vs. HDM+ vehicle 
and HDM+ vehicle vs. HDM+ cynaropicrin.
www.nature.com/scientificreports/
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of cynaropicrin on eosinophils but it cannot be ruled out that the lower numbers we found upon cynaropicrin 
treatment may have been caused by inhibition of rolling, adhesion and migration of eosinophils as was shown 
in a galectin-3 knockout model25. Neutrophils do not express galectin-3 and therefore we do not expect that the 
higher neutrophil numbers can be explained by a direct effect of cynaropicrin on neutrophils26. Galectin-3 in epi-
thelial cells enhances proliferation and therefore intranasally administered cynaropicrin could affect proliferation 
of airway epithelium27. We did not investigate whether proliferation of epithelial cells was affected by cynaropic-
rin treatment, but we did study whether IL-33 production (important for the induction of Th2 responses) by type 
II alveolar epithelial cells was affected by cynaropicrin treatment and we found no effects of cynaropicrin (data 
not shown). In addition, we did not observe any obvious epithelial changes in the histological sections of lung tis-
sue. Furthermore, the expression pattern of galectin-3 is different in an inflammatory environment such as lungs 
of allergic mice28. In lung tissue of these mice it was shown that macrophages are the major cell type expressing 
galectin-3. This may suggest that intranasal cynaropicrin treatment will mostly affect macrophages in mice with 
HDM-induced inflammation.
Even though cynaropicrin does not directly induce polarisation into other macrophage phenotypes, we found 
higher numbers of IRF5+ M1 macrophages, more neutrophils and higher levels of IL-12 in allergic mice that 
were treated with cynaropicrin as compared to untreated allergic mice. Other studies have found similar changes. 
Nieuwenhuizen et al. showed this shift towards the induction of IRF5+ M1 macrophages after blocking signaling 
for M2 polarisation20. Similarly, Hong et al. showed that ovalbumin sensitization and challenge of IL-4 receptor 
knockout mice increased the number of IFNγ- and TNFα- producing macrophages and neutrophilic inflam-
mation29. Thus, our data and those of others suggest that YM1+ M2 macrophages contribute to eosinopilic lung 
inflammation and that inhibition of M2 polarisation during HDM exposures results in a skewing towards M1 
polarisation of macrophages accompanied by neutrophilic inflammation. Therefore, inhibiting M2 polarisation 
as a therapeutic strategy for asthma does not appear to be a beneficial approach as neutrophilic asthma is gen-
erally more difficult to treat in the clinic. Interestingly, in IRF5−/− mice an opposite effect was demonstrated 
by Oriss et al. using a mouse model of severe asthma30. Although IRF5−/− mice subjected to the severe asthma 
model displayed lower IFNγ and IL-17 responses and lower neutrophil numbers, they had higher Th2 responses 
with higher eosinophil numbers. Taken together, these data suggest that the type of macrophages present in lung 
tissue may influence the direction of inflammation in asthma. We did not specifically examine the cytokine/
Healthy
Inhibition of alternative activation during induction of 
allergic lung inflammation
Inhibition of alternative activation after induction 
of allergic lung inflammation
HDM+ vehicle HDM+ Cynaropicrin HDM+ vehicle HDM+ Cynaropicrin
Th1-related cytokines
IL-12 (pg/g lung tissue) 0.62 ± 0.07 1.11 ± 0.31 (*p = 0.0072) 1.52 ± 0.19 (#p = 0.0393) 0.77 ± 0.06 0.89 ± 0.10
IFNγ (pg/g lung tissue) 0.94 ± 0.15 1.60 ± 0.15 (*p = 0.044) 2.52 ± 0.92 (#p = 0.044) 1.38 ± 0.04 (*p = 0.06) 1.34 ± 0.09
TNFα (pg/g lung tissue) 2.1 ± 0.35 3.0 ± 0.25 (*p = 0.044) 6.9 ± 2.8 (#p = 0.044) 2.6 ± 0.27 2.8 ± 0.54
Th17-related cytokines
IL-17 (pg/g lung tissue) 1.0 ± 0.38 2.3 ± 0.27 (*p = 0.0005) 1.78 ± 0.36 2.27 ± 0.67 3.4 ± 1.33
Table 3. Th1-and Th17-related cytokines in lungs of healthy mice, vehicle-treated HDM-exposed mice and 
HDM-exposed mice treated with cynaropicrin during and after induction of allergic lung inflammation. Data 
are presented as mean ± SEM. *Represents the comparison of healthy versus HDM+ vehicle-treated mice, while 
#represents the comparison of HDM+ vehicle versus HDM+ cynaropicrin-treated mice.
Figure 5. Cynaropicrin treatment worsened airway hyperresponsiveness. The dose-response resistance curve 
for methacholine of healthy mice (n = 8), vehicle-treated HDM-exposed mice (n = 16) and HDM-exposed mice 
treated with cynaropicrin (n = 8) during (A) and after induction (B) of allergic lung inflammation. Significance 
was tested using a one-way ANOVA followed by Sidak’s multiple comparisons test comparing the area under 
the curve of healthy vs. HDM+ vehicle and HDM+ vehicle vs. HDM+ cynaropicrin.
www.nature.com/scientificreports/
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chemokine expression by macrophages in this study, but the data suggest that macrophages actively contributed 
to the recruitment of either eosinophils or neutrophils to the site of inflammation. This is reinforced by the fact 
that YM1+ M2 macrophages secrete copious amounts of YM1 that has been shown to be a chemotactic factor for 
eosinophils and IRF5 expression has been shown to control neutrophil chemokine expression31,32. Consequently, 
the clinical implications of these combined results are that inhibition of either neutrophil-or eosinophil-associated 
macrophage phenotypes is not a valid therapeutic option as this may result in domination of the other. The only 
promising therapeutic option that may be investigated for clinical applications therefore appears to be increasing 
the number of IL-10+ M2-like macrophages as we and Moreira et al. have shown before9,13.
An interesting observation in our study is the apparent disconnect between airway hyperresponsiveness and 
the amount of collagen remodeling around the airways. Airway hyperresponsiveness is associated with airway 
smooth muscle hyperplasia, as demonstrated in this study and by others, by a thicker α-SMA layer and more 
collagen deposition around the airways33–35. Our data now demonstrate that this collagen deposition appears to 
protect the airways from even worse contractility. This notion has been coined before and it was considered that 
airway remodeling might actually protect against airway hyperresponsiveness36,37. Although many studies show 
a correlation between airway remodeling and asthma severity, on basis of mathematical modeling assessing the 
effects of airway wall thickening on airway resistance it is unlikely that airway wall thickening can increase air-
way resistance to the extent observed in asthma patients38. In fact, some studies also found that airway reactivity 
was inversely correlated with airway wall thickness36,39. A study that compared males and females with allergic 
airway inflammation had similar findings as we had. The males had lower collagen content in the lungs than 
females, but they found that airway hyperresponsiveness to methacholine was higher in males as compared to 
females40. The authors concluded that the airway hyperresponsiveness is influenced by additional mechanisms, 
which are not necessarily related to remodeling, such as vagal reflex pathways. Our data, however, suggest that 
collagen deposition around the airways, which may contribute to stiffening, can protect against worsening of 
airway hyperresponsiveness.
As YM1+ M2 macrophages are associated with fibrosis, the decrease in collagen deposition may be directly 
linked to the inhibition of M2 polarisation41,42. Therefore, we measured TGF-β levels, as an important mediator 
produced by profibrotic macrophages and a major stimulator of collagen production in the lung tissue, but there 
were no differences between the untreated and treated HDM-induced allergic mice (data not shown)43. Another 
explanation for less collagen in our model could be the high presence of IRF5+ macrophages and its association 
with resolution of fibrosis through production of matrix metalloproteinases that can degrade collagens44.
In conclusion, this study demonstrates an important dual role for YM1+ M2 macrophages in the induc-
tion and progression of allergic lung inflammation. YM1+ M2 macrophages are associated with both induction 
and progression of eosinophilic lung inflammation and airway remodeling. However, inhibition of M2 polarisa-
tion as a therapeutic intervention for asthma has unfortunate consequences as this shifted the balance towards 
more IRF5+ M1 macrophages and neutrophilic lung inflammation and the development of more severe airway 
hyperresponsiveness.
Figure 6. Cynaropicrin treatment results in less airway fibrosis. The area of α-smooth muscle actin (A and B) 
and collagen I and III (C and D) around the airways of healthy mice (n = 8), vehicle-treated HDM-exposed 
mice (n = 16) and HDM-exposed mice treated with cynaropicrin (n = 8) during (left) and after (middle) 
induction of allergic lung inflammation. Representative photos of α-smooth muscle actin and collagen I and III 
stainings with nuclear counter staining are shown (right panels, magnification 200x). Significance was tested 
using a one-way ANOVA followed by Sidak’s multiple comparisons test comparing healthy vs. HDM+ vehicle 
and HDM+ vehicle vs. HDM+ cynaropicrin.
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Materials and Methods
Animals. Specific pathogen free female BALB/c mice (6–8 weeks old) were purchased from Harlan (Horst, 
The Netherlands). The mice were kept in a temperature and light-controlled room and were housed in groups of 
4. There was ad libitum access to water and food. The University of Groningen’s institutional Animal Care and 
Use Committee approved our animal protocol (application number 6272C). All methods were carried out in 
accordance with relevant national and local guidelines and regulations regarding the use of experimental animals 
and proper research conduct.
HDM model and inhibition of alternative activation of macrophages. Female BALB/c mice (n = 16 
per group) were exposed intransally to whole body HDM extract Dermatophagoides Pteronyssinus (Greer labo-
ratories, Lenoir, USA) according to our established 14-day model11. Mice received 100 μg HDM in 40 μl PBS on 
day 0 and 10 μg HDM in 40 μl PBS on day 7–11 intranasally under isoflurane anesthesia to induce allergic lung 
inflammation. Mice exposed to 40 μl PBS according to the HDM protocol served as healthy controls. To inhibit M2 
polarisation of macrophages during induction of lung inflammation mice were exposed intranasally to cynaropicrin 
(2.5 mg/kg in 35 μl 4% DMSO/PBS, BioNaturis, Jerez de la Frontera, Spain). In a preliminary dose-finding study 
using 10, 5 and 2.5 mg/kg cynaropicrin, we found that 2.5 mg/kg inhibited M2 polarisation without signs of toxicity. 
Cynaropicrin was administered on day 7, 9 and 11 right before HDM administration. To study inhibition of M2 
polarisation of macrophages after induction of lung inflammation mice received cynaropicrin on days 14, 16 and 18. 
On day 18, these mice received an exacerbation dose of 10 μg HDM in 40 μl PBS. Control mice received treatment 
with either 35 μl 4% DMSO/PBS or 35 μl PBS but since no significant effect of 4% DMSO was observed these control 
groups were combined. Thus per readout, three experimental groups were studied per model (14 days and 21 days): 
Healthy/PBS-exposed (n = 8), HDM+ vehicle-exposed (n = 16) and HDM+ cynaropcrin-exposed (n = 8). Three 
days after the last exposure the mice were sacrificed. The experimental study design is shown in Fig. 7.
On the day of sacrifice, the lungs of 8 out of 16 mice were lavaged to collect bronchoalveolar lavage fluid 
(BALF). Their left lung lobe was digested for flow cytometry purposes and their right lung lobe was used for 
cytokine analyses. The other 8 mice were used to determine airway hyperresponsiveness and these mice were then 
sacrificed for histological analyses of lung tissue.
Bronchoalveolar lavage fluid (BALF). BALF was collected by gently flushing the lungs with 1 ml of PBS 
three times and BALF supernatants were used to determine the levels of YM1 by ELISA kit (R&D Systems, Oxon, 
UK) strictly following the manufacturer’s instructions.
Lung digestion. The left lung lobe was cut into small pieces and incubated in digestion buffer for 45 min at 
37 °C in a shaking water bath. The digestion buffer was RPMI 1640 medium (Lonza, Verviers, Belgium) contain-
ing 10% fetal calf serum (Lonza), 0.7 mg/ml collagenase A (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 
10 μg/ml DNAse I (grade II from bovine pancreas, Roche Applied Science, Almere, Netherlands). After digestion, 
the lung tissue was forced through a 70 μm nylon strainer (BD Biosciences, Breda, Netherlands) to obtain single 
lung cell suspensions. A 2-minute incubation with 10 times diluted Red Blood Cell lysis buffer (Biolegend, Fell, 
Germany) was done to lyze erythrocytes followed by centrifugation through 70 μm strainer caps. Cells were 
counted using a Casy cell counter (Roche Innovatis AG) and were ready for flow cytometric stainings.
Flow cytometric analysis. T-cell subsets, macrophages, eosinophils, and neutrophils were examined by 
flow cytometry in single cell suspensions using two different cocktails of antibodies.
Frequencies of effector T cells (CD3+CD4+CD25+Foxp3−) and regulatory T cells (CD3+CD4+CD25+Foxp3+) 
were identified using anti-CD3-APC/Cy7 diluted 1:100 (Biolegend, Fell, Germany, catalog number (cat#) 
100221), anti-CD4-PE/Cy7 diluted 1:100 (Biolegend, cat# 100421), anti-CD25-PE diluted 1:100 (Biolegend, cat# 
102008), and anti-Foxp3-FITC diluted 1:100 (eBioscience, Vienna, Austria, cat# 11-5773-82). An isotype control 
was used for the Foxp3 staining diluted 1:100 (rat IgG2ak-FITC, eBioscience, cat# 11-4321-42).
Frequencies of alveolar macrophages (autofluorescence+F4/80+CD11c+), activated alveolar macrophages 
(autofluorescence+F4/80+CD11c+MHCII+), eosinophils (autofluorescence−F4/80−GR1−MHCII−) and neu-
trophils (autofluorescence−F4/80−GR1+) were identified by using autofluorescence in the FITC channel, 
anti-CD11c-APC/Cy7 diluted 1:50 (Biolegend, cat# 117324), anti-CD11b-PerCP/Cy5.5 diluted 1:200 (Biolegend, 
cat# 101227), anti-MHC class II-Alexa Fluor 700 diluted 1:250 (Biolegend, cat# 107622), anti-F4/80-Pacific Blue 
diluted 1:25 (Biolegend, cat# 123124), and anti-GR1-PE/Cy7 diluted 1:200 (Biolegend, cat# 108415).
Approximately 1 × 106 lung cells were incubated for 30 minutes in the dark on ice with the appropriate antibody 
mix including 1% normal mouse serum. After subsequent washing of the cells with PBS containing 2% FCS and 5 mM 
EDTA (PFE), cells were incubated with FACS lysing solution (BD Biosciences) on ice for 30 minutes. Cells were then 
washed twice with PFE, and resuspended in PFE and kept in the dark on ice until flow cytometric analysis. The cells 
stained for T-cell subsets were (instead of incubation with FACS lysing solution) incubated for 30 minutes with fixation 
and permeabilization buffer (eBioscience). After that, cells were washed with permeabilization buffer. Subsequently, the 
cells were incubated for 30 minutes with anti-Foxp3 and afterwards washed twice with permeabilization buffer. Cells 
were resuspended in PFE and kept in the dark at 4 degrees Celsius until flow cytometric analysis. Scatter and fluores-
cence were measured on a LSR-II flow cytometer (BD Biosciences) and data were analysed using FlowJo Software (Tree 
Star, Ashland, USA). Examples or our gating strategies can be found in supplemental Figures S1 and S2.
Lung homogenates and cytokines analysis. A Mini-Beadbeater (Biospec, Bartlesville, OK, USA) was 
used to homogenise snap frozen lung tissue for 45 seconds in 50 mM Tris-HCl buffer, supplemented with 150 mM 
NaCl, 0.002% Tween-20 (pH 7.5) and a Complete Mini Protease Inhibitor Cocktail tablet (1 tablet/10 mL, Sigma 
Aldrich). To remove insoluble material from the homogenates, a 30-minute spin at 12000 × g for 30 minutes was 
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performed. Supernatants were stored at −80 °C until further analysis. Levels of IL-4, IL-10, IL-12, IL-13, IL-17 
and TNFα and IFNγ were measured in lung supernatants by multiplex ELISA (eBioscience).
Airway hyperresponsiveness. Airway hyperresponsiveness was assessed as described previously45. 
Briefly, anesthesized (ketamine/domitor) mice were cannulated tracheally and intravenously via the jugular vein. 
Mice were attached to a computer-controlled small-animal ventilator (Flexivent; SCIREQ, Montreal, Quebec, 
Canada) and ventilated at a breathing frequency of 280 breaths/min and a tidal volume of 10 ml/kg, which was 
pressure-limited at 300 mm H2O. Airway resistance (R in cmH2O.s/mL) in response to increasing doses of intra-
venously administered methacholine (acetyl-b-methylcholine chloride, Sigma-Aldrich) was calculated from the 
pressure response to a 2-s pseudorandom pressure wave.
Histology. Both lungs were carefully filled with 50% Tissue-Tek® O.C.T.™ compound in PBS (Sakura, Finetek 
Europe B.V., Zoeterwoude, The Netherlands) through a cannula inserted in the trachea. The right lung was fixed 
in zinc (JB fixative46) and the left lung was fixed in formalin and both were thereafter embedded in paraffin.
The different macrophage subsets were determined in 3 µm formalin-paraffin sections using standard 
immunohistochemical procedures. Mac3 (anti-Mac3 diluted 1:50, BD Biosciences, cat# 550292), a general 
macrophage marker, was used in combination specific markers for different phenotypes. Numbers of IRF5+ mac-
rophages were determined by a dual stain using Mac3 and IRF5 (anti-IRF5 diluted 1:75, ProteinTech Europe, 
Manchester, UK, cat# 10547-1-AP). YM1+ macrophages were identified by a dual stain using Mac3 and YM1 
(anti-mECF-L diluted 1:50, R&D Systems, Oxon, UK, cat# AF2446), and IL-10+ macrophages were identified by 
a dual stain using Mac3 and IL-10 (anti-IL-10 diluted 1:25, Hycult, Uden, The Netherlands, cat# HP9016). Only 
double-positive cells in parenchymal lung tissue were counted. Numbers were corrected for the total surface area 
of lung tissue as measured by Aperio ImageScope viewing software 11.2.0.780 (Aperio, Vista, USA).
Airway fibrosis and remodeling was assessed by presence of collagen I/III or α-smooth muscle actin. 
Zinc-fixed paraffin sections were stained with anti-type I collagen antibody diluted 1:75 in combination with 
anti-type-III collagen antibody diluted 1:500 (both SouthernBiotec, Birmingham, AL, USA, cat# 1310-01 and 
1330-01 respectively) or anti-α-smooth muscle actin antibody (α-SMA diluted 1:500, Sigma-Aldrich, cat# 
A2547) respectively. Collagen I and III around the airways and the α-SMA-positive layer directly adjacent to the 
airway epithelium were quantified in a total lung section by morphometric analysis. The surface of the positively 
stained area was expressed as μm2 per mm airway in the total lung section. Staining in the parenchyma and 
directly adjacent to blood vessels was excluded.
Statistical Analysis. Results are presented as mean ± standard error of the mean. To verify whether data 
were normally distributed a D’Agostino & Pearson omnibus normality test was used. When data were not nor-
mally distributed they were log transformed to obtain a normal distribution. A one-way ANOVA followed 
by Sidak’s multiple comparisons test was used to compare healthy vs. HDM+ vehicle and HDM+ vehicle vs. 
HDM+ cynaropicrin. Differences in airway resistance were tested by comparing the area under the curve of 
healthy vs. HDM+ vehicle and HDM+ vehicle vs. HDM+ cynaropicrin. Differences were considered statistically 
significant when the P-value was lower than 0.05.
Figure 7. Experimental design of the study.
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Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author upon reasonable request.
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